These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19138011)

  • 1. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone loss in prostate cancer: evaluation, treatment and prevention.
    Saad F
    Can J Urol; 2005 Feb; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N; Huynh CC; Rashid P
    Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K; Machida T; Yoshida K
    Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
    Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.